Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 28, 2022Drug Discoveries & TherapeuticsOpen Access

Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain

View Full Paper
Ask AI
Bookmark
Share

Why the study?

To provide an overview of real-world data on the use of tofacitinib in patients with active rheumatoid arthritis in Spain.

What are the real-world treatment patterns, effectiveness, and safety of tofacitinib in patients with active rheumatoid arthritis in Spain?

Population

Approximately 511 patients with active rheumatoid arthritis from 16 retrospective studies in Spain…

Design

Review

Authors

JIJose Andrés Román IvorraNLNoelia LlevatMMMaría Montoro

Discussion

Loading...

Member takes

Overview

Spanish real-world tofacitinib data in RA summarized; leaves open efficacy and safety questions for prospective trials.

Structured PICO

What are the real-world treatment patterns, effectiveness, and safety of tofacitinib in patients with active rheumatoid arthritis in Spain?

P
Population
Approximately 511 patients with active rheumatoid arthritis (RA) from 16 retrospective studies in Spain, predominantly women, mean age 48-61 years. 36.0-85.7% had failed a previous biological disease-modifying anti-rheumatic drug.
I
Intervention
Tofacitinib (as monotherapy in 20.0-67.9% or combined with corticosteroids in 42.0-84.5%)
O
Outcome
Treatment patterns, effectiveness, and safety

Real-world data from Spain confirms the effectiveness and safety profile of tofacitinib in rheumatoid arthritis, with herpes zoster as the most common adverse event.

Cite This Study

Ivorra et al. (2022) studied this question.

synapsesocial.com/papers/6a728cc16c240de38cdc696dhttps://doi.org/10.5582/ddt.2022.01028
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician2018 · 739 citations
  2. 22015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis2015 · 2,811 citations
  3. 3Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate2011 · 299 citations
  4. 4Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme2020 · 186 citations